How Much Do Diabetes Medications Cost by Insurance Tier in 2026?

Diabetes medications occupy every rung of the Medicare Part D formulary ladder, from $4 generic metformin on Tier 1 to $1,350 specialty injectables on Tier 4 and Tier 5. Formulary tiers are the cost-sharing categories a Part D or commercial insurance plan assigns to each covered drug: Tier 1 (preferred generic), Tier 2 (generic or preferred brand), Tier 3 (non-preferred brand), and Tier 4 or Tier 5 (specialty). The tier a specific diabetes drug lands on determines your copay or coinsurance, and it explains why two patients with the same diagnosis can pay wildly different amounts for their prescriptions. Metformin and the sulfonylureas (glipizide, glyburide) sit on Tier 1 at nearly every plan because they have been off-patent for decades. Jardiance, Farxiga, and Januvia carry lower effective cost-sharing in 2026 because the Inflation Reduction Act negotiated Medicare Maximum Fair Prices for all three. Ozempic, Trulicity, Mounjaro, and Zepbound remain on Tier 3, Tier 4, or specialty tiers at most plans because they lack IRA negotiation, generic competition, or both. This guide compares real 2026 costs across every tier so you can see exactly where your prescription falls and what options exist to move it lower.

The Inflation Reduction Act of 2022 (Public Law 117-169, signed August 16, 2022) authorized Medicare to negotiate drug prices directly with manufacturers for the first time, and diabetes drugs make up 4 of the first 10 drugs selected. Jardiance (empagliflozin), Farxiga (dapagliflozin), Januvia (sitagliptin), and Fiasp/NovoLog (insulin aspart) all carry Medicare Maximum Fair Prices effective January 1, 2026, cutting their list prices by 66 to 79 percent for Part D enrollees. Semaglutide, sold as Ozempic for type 2 diabetes and Wegovy for weight loss, was selected for the second round of negotiation; that Maximum Fair Price does not take effect until January 1, 2027. Trulicity (dulaglutide), Mounjaro, and Zepbound (tirzepatide) have not been selected for any negotiation round as of 2026 and remain priced at full Tier 3 or Tier 4 formulary cost-sharing. Meanwhile, generic sitagliptin entered pharmacies in May 2026 and generic dapagliflozin arrived in April 2026, adding a second cost-reduction path on top of the negotiated Medicare price for two of the four IRA-negotiated diabetes drugs. See Jardiance cost and Farxiga cost for single-drug detail.

Insulin sits in its own cost category regardless of formulary tier. Every insulin product, brand, biosimilar, or authorized generic, is capped at $35 per fill for Medicare Part D enrollees under the Inflation Reduction Act, effective since January 1, 2023. That statutory cap applies whether a patient uses brand Lantus, the interchangeable biosimilar Semglee, or Eli Lilly's Basaglar. GLP-1 receptor agonists occupy the opposite extreme: Ozempic, Trulicity, Mounjaro, and Zepbound retail for $950 to $1,350 per month, and most commercial and Medicare plans place them on non-preferred or specialty tiers with prior authorization requirements. Patients priced out of any tier should compare the Medicaid income limits for their state, since Medicaid covers most diabetes drug classes with a $1 to $8 copay regardless of brand-name formulary tier placement.

What Diabetes Drug Cost by Tier Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same diabetes drug cost by tier can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Hospital inpatient billing erases almost all of the formulary-tier distinctions that matter at the outpatient pharmacy counter. A Tier 1 metformin tablet that costs about 15 cents at retail can appear on an itemized hospital bill at $50 to $200 per dose, because hospitals bundle drug acquisition cost with nursing administration, pharmacy handling, and facility overhead into a single chargemaster rate. A Tier 4 Ozempic pen with a $750 to $850 wholesale acquisition cost can be billed at $1,500 to $4,000 for a partial dose administered during a stay. In both cases, the markup has nothing to do with the drug's formulary tier at your Part D plan; it reflects the hospital's internal pricing structure, which most insurers absorb into a bundled Diagnosis-Related Group (DRG) payment under Medicare Part A rather than paying the itemized line item directly.

Medicare Part A stops covering any of these drugs the moment a patient is discharged, and coverage shifts entirely to Part D for the outpatient prescription. That transition is exactly where the 2026 IRA Maximum Fair Prices for Jardiance, Farxiga, Januvia, and Fiasp/NovoLog take effect, along with the $35 insulin cap and standard formulary cost-sharing for drugs like Trulicity and Ozempic. Patients discharged on a new diabetes prescription without an active Part D plan often get sticker shock at the outpatient pharmacy, because the inpatient DRG rate never applies again once they leave the building. Anyone leaving a hospital stay on a new diabetes medication should call 1-800-MEDICARE or their Part D plan before the first outpatient fill to confirm the tier placement and negotiated 2026 price.

HCPCS J-Codes: What Appears on Your Bill

Most diabetes medications carry no HCPCS J-code because they are oral tablets or self-administered injections billed under Medicare Part D, not Part B. Insulin is the exception when it is delivered through a durable medical equipment (DME) insulin pump or administered by a provider in a clinical setting.

Patient Assistance Programs

Five manufacturers dominate the diabetes drug market, and each runs its own income-based patient assistance program (PAP) for uninsured patients, separate from any commercial manufacturer coupon. The program and income threshold depend entirely on which specific drug and manufacturer you take, so a Trulicity patient must apply to Lilly Cares while a Farxiga patient applies to AstraZeneca's AZ&Me program.

Medicare Part D

Medicare Part D treats the five diabetes drug classes very differently in 2026. Metformin and sulfonylureas sit on Tier 1 with a $0 to $5 copay on almost every plan. Jardiance, Farxiga, and Januvia carry IRA-negotiated Maximum Fair Prices of $197, $178.50, and $113 per month respectively, applied at any network pharmacy regardless of which specific Part D plan you carry. Every insulin product, whether brand, biosimilar, or authorized generic, is capped at $35 per fill under the Inflation Reduction Act, a separate statutory protection that has applied since January 1, 2023. Trulicity, Ozempic, Mounjaro, and Zepbound have no negotiated Medicare price or specific cap in 2026; their out-of-pocket cost depends entirely on your plan's formulary tier and typically requires prior authorization. All out-of-pocket spending across every diabetes drug you take counts toward the same 2026 Part D annual out-of-pocket cap of $2,100; once you hit that cap, you pay $0 for the rest of the calendar year.

Extra Help (the Part D Low Income Subsidy) reduces cost-sharing further for Medicare beneficiaries with limited income and resources, generally at or below 150% of the Federal Poverty Level. In 2026, Extra Help enrollees pay approximately $4.90 per fill for a Tier 1 generic like metformin and $12.65 per fill for a brand-name drug like Jardiance, Farxiga, or Ozempic, regardless of the drug's list price. Apply through the Social Security Administration at 1-800-772-1213 or at ssa.gov. If your Part D plan is charging more than the published Maximum Fair Price for Jardiance ($197), Farxiga ($178.50), or Januvia ($113) in 2026, contact your plan's member services and ask them to reprocess the claim; federal law requires every Part D plan to honor these negotiated prices.

Common Diabetes Drug Cost by Tier Billing Errors

Because diabetes drugs span so many formulary tiers and pricing rules, billing errors are common. Check for these issues before paying an unexpected bill:

• Part D plan charged more than the $197 Jardiance, $178.50 Farxiga, or $113 Januvia Maximum Fair Price for a 2026 fill, which violates federal law
• Insulin billed above the $35 statutory Part D cap regardless of brand, biosimilar, or generic status
• Generic sitagliptin or dapagliflozin billed at the brand-name Tier 3 rate instead of the generic Tier 1 or Tier 2 rate
• Manufacturer savings card or coupon applied for a patient who has Medicare, Medicaid, TRICARE, or VA, which is prohibited by federal anti-kickback law and can trigger a later claim clawback
• Wrong diabetes drug billed under the wrong NDC, for example Basaglar's code appearing on a claim when brand Lantus was actually dispensed
• Charged the standard copay after already hitting the $2,100 Part D annual out-of-pocket cap for the year across all combined Part D drugs

Frequently Asked Questions